Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants. Our localized approach represents a significant change from the systemic immunosuppression of conventional medicines, which often have dose-limiting safety concerns and can cause serious infections and cancer. Furthermore, through tissue-specific therapeutic targeting, Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. We aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.
Pandion’s four founders, all experienced leaders in drug discovery, translation and clinical development, were brought together by a common recognition: that the time was right to introduce a new approach for treating autoimmune and inflammatory diseases and enabling transplantation tolerance. Recent advances in the fields of immunology and immuno-oncology have resulted in new insights into regulating the immune system in more precise and localized ways, which our founders sought to harness for autoimmune and inflammatory diseases and transplantation. Furthermore, recent developments in the protein engineering field have inspired the founders to focus on a bispecific antibody-based approach to induce local immunomodulation.
We are taking an aggressive approach to drug development, with a focus on advancing our lead molecules while simultaneously building our technology platform and pipeline. Our initial indications of interest include inflammatory bowel disease, autoimmune liver disease, kidney diseases, type 1 diabetes, and autoimmune skin conditions. We are actively pursuing partners for a number of these programs.
Pandion was founded in early 2017 and seed funded by Polaris Partners. We closed a $58M Series A financing in early 2018, co-led by Polaris, Versant Ventures, and Roche Venture Fund, with participation from SR One and BioInnovation Capital. We have office and laboratory space at LabCentral in Cambridge, Massachusetts.